We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+19.87%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
+$244M
Cap. Flow
+$74.7M
Cap. Flow %
4.68%
Top 10 Hldgs %
27.52%
Holding
150
New
14
Increased
55
Reduced
10
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$36M
2
AMRN
Amarin Corp
AMRN
+$13.9M
3
TSRO
TESARO, Inc.
TSRO
+$13.7M
4
DHR icon
Danaher
DHR
+$12.8M
5
PTHN
Patheon N.V.
PTHN
+$11M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$19.8M
2
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18M
3
TMO icon
Thermo Fisher Scientific
TMO
+$14.8M
4
MD icon
Pediatrix Medical
MD
+$9.92M
5
XNPT
XENOPORT, INC.
XNPT
+$8.41M

Sector Composition

Rank Sector Weight
1 Healthcare 81.88%
2 Financials 3.67%
3 Industrials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRPT icon
51
Sarepta Therapeutics
SRPT
$1.77B
$10.6M 0.67%
173,000
+42,000
+32% +$1.27M
RARE icon
52
Ultragenyx Pharmaceutical
RARE
$2.55B
$10.4M 0.65%
147,000
+5,500
+4% +$351K
HOLX
53
DELISTED
Hologic
HOLX
$9.8M 0.61%
252,500
+22,500
+10% +$849K
FPRX
54
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$8.73M 0.55%
166,250
+13,250
+9% +$633K
BOLD
55
DELISTED
Audentes Therapeutics, Inc
BOLD
$8.64M 0.54%
+485,000
New +$7.36M
ALKS icon
56
Alkermes
ALKS
$8.25B
$8.61M 0.54%
183,027
-11,473
-6% -$546K
EXAS
57
DELISTED
Exact Sciences
EXAS
$8.08M 0.51%
+435,000
New +$7.67M
VRTX icon
58
Vertex Pharmaceuticals
VRTX
$126B
$7.83M 0.49%
89,750
+4,250
+5% +$402K
NVTA
59
DELISTED
Invitae Corporation
NVTA
$7.8M 0.49%
890,000
+31,620
+4% +$266K
WTW icon
60
Willis Towers Watson
WTW
$32B
$7.77M 0.49%
+58,500
New +$7.28M
HRC
61
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$7.44M 0.47%
120,000
– –
CRVS icon
62
Corvus Pharmaceuticals
CRVS
$1.17B
$7.4M 0.46%
450,000
– –
INSM icon
63
Insmed
INSM
$28.6B
$7.3M 0.46%
503,000
+5,500
+1% +$68.8K
KA
64
DELISTED
Kineta, Inc. Common Stock
KA
$7.02M 0.44%
3,214
+250
+8% +$465K
ONC
65
BeOne Medicines Ltd
ONC
$39.4B
$6.93M 0.43%
225,000
– –
REGN icon
66
Regeneron Pharmaceuticals
REGN
$80.8B
$6.83M 0.43%
17,000
– –
ISEE
67
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$6.83M 0.43%
148,000
+5,500
+4% +$310K
MGNX icon
68
MacroGenics
MGNX
$257M
$6.73M 0.42%
225,000
– –
RIGL icon
69
Rigel Pharmaceuticals
RIGL
$750M
$6.64M 0.42%
181,000
+6,000
+3% +$172K
LGND icon
70
Ligand Pharmaceuticals
LGND
$6.36B
$6.63M 0.42%
+104,195
New +$7.65M
PRTK
71
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$6.54M 0.41%
502,500
+84,000
+20% +$1.11M
EVHC
72
DELISTED
Envision Healthcare Holdings Inc
EVHC
$6.48M 0.41%
97,194
– –
NVDQ
73
DELISTED
Novadaq Technologies Inc.
NVDQ
$6.42M 0.4%
555,000
– –
MRUS
74
DELISTED
Merus
MRUS
$6.42M 0.4%
383,000
+22,189
+6% +$211K
EPZM
75
DELISTED
Epizyme, Inc
EPZM
$6.32M 0.4%
642,500
+45,000
+8% +$411K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rock Springs Capital Management held 150 positions worth $1.6B, up 18% from $1.35B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $74.7M of net new capital in Q3 2016, opening 14 new positions and adding to 55 existing holdings. Its largest new stake was Merck: 615,700 shares worth $36.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Pediatrix Medical, an estimated $9.92M trimmed.

  • Rock Springs Capital Management's largest Q3 2016 buy was Merck: 615,700 shares worth $36.7M.
  • Rock Springs Capital Management added most to TESARO, Inc. in Q3 2016, an estimated $13.7M increase.
  • Rock Springs Capital Management's biggest Q3 2016 reduction was Pediatrix Medical, cutting an estimated $9.92M.
  • Rock Springs Capital Management fully exited Teva Pharmaceuticals in Q3 2016, selling an estimated $19.8M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.6B portfolio in Q3 2016.
  • Rock Springs Capital Management opened 14 new positions and closed 13 in Q3 2016.
  • Rock Springs Capital Management's portfolio value rose 18% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.